184 related articles for article (PubMed ID: 10575653)
21. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
Ingelman-Sundberg M; Johansson I; Persson I; Yue QY; Dahl ML; Bertilsson L; Sjöqvist F
Pharmacogenetics; 1992 Dec; 2(6):264-71. PubMed ID: 1306127
[TBL] [Abstract][Full Text] [Related]
22. [Individual susceptibility factors in the risk of lung cancer].
Stücker I
Ann Pathol; 1997; 17 Suppl 5():23-4. PubMed ID: 9453718
[No Abstract] [Full Text] [Related]
23. [Genetic and phenotypic polymorphisms in carcinogen-metabolizing enzymes and cancer susceptibility].
Watanabe M
Nihon Rinsho; 1996 Aug; 54(8):2261-75. PubMed ID: 8810806
[TBL] [Abstract][Full Text] [Related]
24. Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss.
Saijo Y; Sata F; Yamada H; Suzuki K; Sasaki S; Kondo T; Gong YY; Kato EH; Shimada S; Morikawa M; Minakami H; Kishi R
Mol Hum Reprod; 2004 Oct; 10(10):729-33. PubMed ID: 15299091
[TBL] [Abstract][Full Text] [Related]
25. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
26. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
27. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics.
Miksys S; Tyndale RF
Drug Metab Rev; 2004 May; 36(2):313-33. PubMed ID: 15237857
[TBL] [Abstract][Full Text] [Related]
28. [Polymorphisms in detoxification genes CYP1A1, CYP2E1, GSTT1 and GSTM1 in gastric cancer susceptibility].
González A; Ramírez V; Cuenca P; Sierra R
Rev Biol Trop; 2004 Sep; 52(3):591-600. PubMed ID: 17361553
[TBL] [Abstract][Full Text] [Related]
29. Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer.
Shah PP; Singh AP; Singh M; Mathur N; Mishra BN; Pant MC; Parmar D
Mutat Res; 2008 Aug; 643(1-2):4-10. PubMed ID: 18573508
[TBL] [Abstract][Full Text] [Related]
30. [Biology of bronchial cancer. Molecular epidemiology].
Urban T
Rev Mal Respir; 1999 Jan; 16 Suppl 3():S13-4. PubMed ID: 10088222
[No Abstract] [Full Text] [Related]
31. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1.
Reid JM; Kuffel MJ; Miller JK; Rios R; Ames MM
Clin Cancer Res; 1999 Aug; 5(8):2192-7. PubMed ID: 10473105
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome P450 expression (CYP) in non-small cell lung cancer.
Oyama T; Sugio K; Uramoto H; Kawamoto T; Kagawa N; Nadaf S; Carbone D; Yasumoto K
Front Biosci; 2007 Jan; 12():2299-308. PubMed ID: 17127240
[TBL] [Abstract][Full Text] [Related]
33. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacogenetics].
Hach I; Kirch W
Praxis (Bern 1994); 2008 Oct; 97(21):1127-9. PubMed ID: 18951351
[No Abstract] [Full Text] [Related]
35. Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility.
Hatagima A
Cad Saude Publica; 2002; 18(2):357-77. PubMed ID: 11923879
[TBL] [Abstract][Full Text] [Related]
36. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes.
Daly AK; Fairbrother KS; Smart J
Toxicol Lett; 1998 Dec; 102-103():143-7. PubMed ID: 10022246
[TBL] [Abstract][Full Text] [Related]
38. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells.
Zhao W; Parrish AR; Ramos KS
In Vitro Cell Dev Biol Anim; 1998 Oct; 34(9):671-3. PubMed ID: 9794216
[No Abstract] [Full Text] [Related]
39. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics.
Ingelman-Sundberg M
Arch Toxicol Suppl; 1997; 19():3-13. PubMed ID: 9079190
[No Abstract] [Full Text] [Related]
40. Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.
Lee HC; Yoon YB; Kim CY
Korean J Intern Med; 1997 Jun; 12(2):128-36. PubMed ID: 9439147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
